On June 21, 2007, CDC's Investigational New Drug Application (IND) for intravenous artesunate went into effect. This IND allows for use of an investigational anti-malarial medication (intravenous artesunate) under a protocol entitled "Intravenous Artesunate for Treatment of Severe Malaria in the United States." Intravenous artesunate can be used only under the provisions of this IND protocol because it is not a drug approved by the Food and Drug Administration (FDA). Artesunate is in the class of medications known as artemisinins, which are derivatives from "quing hao," or sweet wormwood plant (Artemisia annua). Only the CDC Drug Service and CDC Quarantine Stations will be permitted to release the medication for use under this IND protocol. mohegan sun gambling ctr can blackjack be profitable online?? what states prohibit gambling gambling loss tax deduction miccasoukee gambling florida